| 2.07 0.08 (4.02%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.58 | 1-year : | 2.79 |
| Resists | First : | 2.21 | Second : | 2.39 |
| Pivot price | 2.07  |
|||
| Supports | First : | 1.93 | Second : | 1.6 |
| MAs | MA(5) : | 2.01 |
MA(20) : | 2.07 |
| MA(100) : | 2.5 |
MA(250) : | 2.2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 16.9 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 5.21 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CELU ] has closed above bottom band by 48.4%. Bollinger Bands are 69.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 1.97 - 1.98 | 1.98 - 1.99 |
| Close: | 2.05 - 2.07 | 2.07 - 2.09 |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Wed, 03 Sep 2025
$41.6M Debt Retired: Biotech Celularity Clears Financial Hurdles with Q1-Q2 Filings, Keeps Nasdaq Listing - Stock Titan
Wed, 03 Sep 2025
Celularity Announces Filing of Form 10-Q Quarterly Reports - GlobeNewswire
Fri, 22 Aug 2025
Biotech Celularity Faces Nasdaq Compliance Challenge Over Two Missing Quarterly Reports - Stock Titan
Mon, 18 Aug 2025
$41.6 Million Debt Eliminated: Celularity Restructures Balance Sheet with Strategic IP Sale and Exclusive License Back - Stock Titan
Mon, 18 Aug 2025
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 1.45e+007 (%) |
| Held by Institutions | 39.9 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.991e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -165.3 % |
| Operating Margin | -276.6 % |
| Return on Assets (ttm) | -23.2 % |
| Return on Equity (ttm) | -6 % |
| Qtrly Rev. Growth | 4.459e+007 % |
| Gross Profit (p.s.) | -69.22 |
| Sales Per Share | 483.21 |
| EBITDA (p.s.) | 3.23289e+007 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.52 |
| Dividend | 0 |
| Forward Dividend | 640090 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|